BeiGene reports Phase I data for pamiparib in ovarian cancer

BeiGene Ltd. (NASDAQ:BGNE) reported preliminary data from nine evaluable ovarian cancer patients in the dose-escalation portion of a Phase

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE